Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.22.2
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 16, 2020
Nov. 01, 2006
Feb. 28, 2009
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Licensing and other arrangements                
Revenue from contracts with customers       $ 525 $ 525 $ 3,275 $ 544  
Takeda | Collaboration Agreement                
Licensing and other arrangements                
Revenue from contracts with customers $ 2,000     0 $ 0 800 $ 0  
Contract assets       0   0   $ 0
Contract liabilities       0   0   0
Capitalized contract costs       0   0   $ 0
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       $ 16,000   $ 16,000    
Takeda | Collaboration Agreement | TAK-079                
Licensing and other arrangements                
Royalty payment period   13 years 6 months            
Royalty payment period from the first commercial sale of each royalty-bearing discovery product   12 years            
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 19,000            
Takeda | Collaboration Agreement | Other antibodies                
Licensing and other arrangements                
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300          
Royalty payment period     10 years